Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Current management of hemophilia A includes prophylaxis with factor VIII (FVIII) replacement every 2 to 3 days. BAX 855, Baxalta’s pegylated full-length recombinant FVIII (rFVIII), was designed to increase half-life and, thus, reduce the frequency of prophylactic infusions while maintaining hemostat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Konkle, Barbara A., Stasyshyn, Oleksandra, Chowdary, Pratima, Bevan, David H., Mant, Tim, Shima, Midori, Engl, Werner, Dyck-Jones, Jacqueline, Fuerlinger, Monika, Patrone, Lisa, Ewenstein, Bruce, Abbuehl, Brigitt
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4551361/
https://ncbi.nlm.nih.gov/pubmed/26157075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-03-630897
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados